M G Harmsen1, M Arts-de Jong2, K Horstik2, P Manders3, L F A G Massuger2, R P M G Hermens4, N Hoogerbrugge3, G H Woldringh3, J A de Hullu2. 1. Department of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Marline.Harmsen@radboudumc.nl. 2. Department of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands. 3. Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands. 4. Scientific Institute for Quality of Healthcare, Radboud University Medical Center, Nijmegen, The Netherlands.
Abstract
OBJECTIVE: Risk-reducing salpingo-oophorectomy (RRSO) is the only effective surgical strategy to reduce the increased risk of epithelial ovarian cancer in BRCA1/2 mutation carriers. Given the long-term health consequences of premature surgical menopause, we need insight in uptake and timing of RRSO to guide us in improving healthcare. METHODS: A single-center retrospective cohort study of BRCA1/2 mutation carriers diagnosed and counseled at the multidisciplinary Family Cancer Clinic of the Radboud university medical center in Nijmegen, The Netherlands, between 1999 and 2014. Descriptive statistics were used to analyze uptake and timing of RRSO. RESULTS: Data of 580 BRCA1/2 were analyzed. The uptake of RRSO among mutation carriers who are currently above the upper limit of the recommended age for RRSO, is 98.5% and 97.5% for BRCA1 and BRCA2 mutation carriers, respectively. The vast majority undergoes RRSO ≤40 (BRCA1) or ≤45 (BRCA2) years of age, provided that mutation status is known by that age: 90.8% and 97.3% of BRCA1 and BRCA2 mutation carriers, respectively. CONCLUSIONS: The uptake of RRSO among BRCA1/2 mutation carriers who were counseled at our Family Cancer Clinic is extremely high. High uptake might be largely attributed to the directive and uniform way of counseling by professionals at our Family Cancer Clinic. Given the fact that RRSO is often undergone at premenopausal age in our population, future research should focus on minimizing long-term health consequences of premature surgical menopause either by optimization of hormone replacement therapy or by investigating alternative strategies to RRSO.
OBJECTIVE: Risk-reducing salpingo-oophorectomy (RRSO) is the only effective surgical strategy to reduce the increased risk of epithelial ovarian cancer in BRCA1/2 mutation carriers. Given the long-term health consequences of premature surgical menopause, we need insight in uptake and timing of RRSO to guide us in improving healthcare. METHODS: A single-center retrospective cohort study of BRCA1/2 mutation carriers diagnosed and counseled at the multidisciplinary Family Cancer Clinic of the Radboud university medical center in Nijmegen, The Netherlands, between 1999 and 2014. Descriptive statistics were used to analyze uptake and timing of RRSO. RESULTS: Data of 580 BRCA1/2 were analyzed. The uptake of RRSO among mutation carriers who are currently above the upper limit of the recommended age for RRSO, is 98.5% and 97.5% for BRCA1 and BRCA2 mutation carriers, respectively. The vast majority undergoes RRSO ≤40 (BRCA1) or ≤45 (BRCA2) years of age, provided that mutation status is known by that age: 90.8% and 97.3% of BRCA1 and BRCA2 mutation carriers, respectively. CONCLUSIONS: The uptake of RRSO among BRCA1/2 mutation carriers who were counseled at our Family Cancer Clinic is extremely high. High uptake might be largely attributed to the directive and uniform way of counseling by professionals at our Family Cancer Clinic. Given the fact that RRSO is often undergone at premenopausal age in our population, future research should focus on minimizing long-term health consequences of premature surgical menopause either by optimization of hormone replacement therapy or by investigating alternative strategies to RRSO.
Authors: Stephanie Kearton; Karen Wills; Michael Bunting; Penny Blomfield; Paul A James; Jo Burke Journal: Fam Cancer Date: 2018-07 Impact factor: 2.375
Authors: Marline G Harmsen; Miranda P Steenbeek; Nicoline Hoogerbrugge; Helena C van Doorn; Katja N Gaarenstroom; M Caroline Vos; Leon F A G Massuger; Joanne A de Hullu; Rosella P M G Hermens Journal: Health Expect Date: 2017-12-27 Impact factor: 3.377
Authors: Janet R Vos; Ingrid E Fakkert; Joanne A de Hullu; Anne M van Altena; Aisha S Sie; Hicham Ouchene; Riki W Willems; Iris D Nagtegaal; Marjolijn C J Jongmans; Arjen R Mensenkamp; Gwendolyn H Woldringh; Johan Bulten; Edward M Leter; C Marleen Kets; Michiel Simons; Marjolijn J L Ligtenberg; Nicoline Hoogerbrugge Journal: J Natl Cancer Inst Date: 2020-02-01 Impact factor: 13.506
Authors: Lara Terra; Maartje J Hooning; Bernadette A M Heemskerk-Gerritsen; Marc van Beurden; Jeanine E Roeters van Lennep; Helena C van Doorn; Joanne A de Hullu; Constantijne Mom; Eleonora B L van Dorst; Marian J E Mourits; Brigitte F M Slangen; Katja N Gaarenstroom; M Carola Zillikens; Tim Leiner; Lizet van der Kolk; Margriet Collee; Marijke Wevers; Margreet G E M Ausems; Klaartje van Engelen; Lieke Pv Berger; Christi J van Asperen; Encarna B Gomez-Garcia; Irma van de Beek; Matti A Rookus; Michael Hauptmann; Eveline M Bleiker; Sanne B Schagen; Neil K Aaronson; Angela H E M Maas; Flora E van Leeuwen Journal: JMIR Res Protoc Date: 2021-01-22
Authors: Jamie E Clarke; Stephanie Magoon; Irman Forghani; Francesco Alessandrino; Gina D'Amato; Emily Jonczak; Ty K Subhawong Journal: Eur J Radiol Open Date: 2022-04-25
Authors: Sukh Makhnoon; Grace Tran; Brooke Levin; Kristin D Mattie; Brian Dreyer; Robert J Volk; Generosa Grana; Banu K Arun; Susan K Peterson Journal: Cancer Date: 2021-06-22 Impact factor: 6.860